

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

28 October 2013

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(11 pages by email)


Dear Madam

BIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013

Biotron Limited ('Biotron') is today presenting at Australia Biotech Invest 2013 in Melbourne, Australia. The conference provides a unique opportunity to showcase the Company's product pipeline and its investment potential to an international audience of investors and potential partners.

A copy of the presentation is attached.

Yours sincerely



Peter J. Nightingale
Company Secretary

About Biotron and BIT225

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

BIT225 has recorded highly encouraging data against HCV in clinical trials. A phase 2a trial in HCV demonstrated that 100% of HCV genotype 1-infected patients receiving BIT225 (400 mg) in combination with current standard of care therapies interferon and ribavirin had undetectable virus after 48 weeks.

BIT225 is also in development for treatment of HIV, and is the first in a new class of antiviral drugs that may provide a new approach to eradication of this virus. It has shown clinical efficacy against HIV in reservoir cells, and has the potential to be combined with new or existing anti-retroviral drugs to eradicate long-lived pools of virus that are not eliminated with current treatments.

A further phase 2 trial, 3 month-dosing trial of BIT225 in HCV genotype 1 and 3-infected patients is anticipated to commence in late 2013.